 |
Hugel |
[Alpha Biz= Reporter Kim Sangjin] On August 7, Hugel reported its Q2 2024 financial results, with consolidated revenue of 95.4 billion won and operating profit of 42.4 billion won. Both figures represent significant increases of 17% in revenue and 51.6% in operating profit compared to the same period last year. This marks the first time Hugel has achieved quarterly revenues and operating profits exceeding 90 billion won and 40 billion won, respectively, setting new records.
By product category, sales of the botulinum toxin product Botulax increased by 17.6% compared to the previous year, with growth observed in both domestic and global markets, particularly in the Asia-Pacific and European regions. Hyaluronic acid (HA) fillers also saw a 20% increase in sales, demonstrating stable growth. The cosmetics sector experienced over a 10% increase in revenue.
Looking ahead, Hugel plans to focus on expanding its presence in international markets. This includes starting shipments of Botulax (export name Retibo) to the U.S. market and concentrating on establishing a strong foothold in North America, including Canada.
Alphabiz Reporter Kim SangJin(letyou@alphabiz.co.kr)
